RT @mayogastro: Excelente. Esta vacuna parece efectiva con pocos efectos 2rios. Immunogenicity and safety of a recombinant adenovirus type-…
RT @FabBallarini: BUENAS NOTICIAS Se acaban de publicar 2 papers contando los avances sobre 2 vacunas. En ambos casos se muestra respuest…
RT @melquiadess: El mundo siempre está mejorando: dos nuevas vacunas contra COVID-19 mostraron ser capaces de generar respuesta inmune (ant…
RT @FabBallarini: BUENAS NOTICIAS Se acaban de publicar 2 papers contando los avances sobre 2 vacunas. En ambos casos se muestra respuest…
笑笑🤣🤣🤣🤣 今朝このツイート見て、俺もかなりやられてるな〜☣️ なんて思いましたよ なぜかって? Ad5-nCoV(アデノウイルスベクター)P2ってところで、寝ぼけてた俺は「えっ、何?コロナ殺す為にできたワクチンの名前、アベノウイルスベクターなの?どんだけ〜🥱って見間違いをしてしまいました苦笑
RT @TheLancet: Phase 3 trials are needed to confirm whether the vaccine candidate effectively protects against SARS-CoV-2 infection https:/…
RT @TheLancet: Just added to The Lancet's #COVID19 Resource Centre—Safety and immunogenicity of two COVID-19 vaccine trials: ChAdOx1 https:…
RT @iaiestaran: Vacuna china en fase 2 resulta segura y produce respuesta inmune en la epidemia de coronavirus #COVID19, según estudio publ…
RT @TheLancet: Just added to The Lancet's #COVID19 Resource Centre—Safety and immunogenicity of two COVID-19 vaccine trials: ChAdOx1 https:…
RT @EricTopol: And another adenovirus vector vaccine Phase 2 trial (CanSIno) in China, published @TheLancet today, also found neutralizing…
RT @AB_Algaissi: أخبار جميلة اليوم عن اللقاحات: نشر نتائج المرحلة السريرية ١ للقاح جامعة أكسفورد والنتائج مشجعة جداً. https://t.co/qzBJVYI…
RT @TheLancet: Just added to The Lancet's #COVID19 Resource Centre—Safety and immunogenicity of two COVID-19 vaccine trials: ChAdOx1 https:…
RT @iaiestaran: Vacuna china en fase 2 resulta segura y produce respuesta inmune en la epidemia de coronavirus #COVID19, según estudio publ…
RT @pmarsupia: 🔴 Más buenas noticias! The Lancet también ha publicado los resultados de la Fase II de la farmacéutica china CanSino (sí,…
RT @NunuX20: Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or olde…
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
RT @mayogastro: Excelente. Esta vacuna parece efectiva con pocos efectos 2rios. Immunogenicity and safety of a recombinant adenovirus type-…
RT @pmarsupia: 🔴 Más buenas noticias! The Lancet también ha publicado los resultados de la Fase II de la farmacéutica china CanSino (sí,…
RT @iaiestaran: Vacuna china en fase 2 resulta segura y produce respuesta inmune en la epidemia de coronavirus #COVID19, según estudio publ…
イギリスのグループと中国のグループが、それぞれ、健常者への新型コロナSARS-CoV-2ワクチンの接種でT細胞反応と抗体の出現を確認したと報告しました。 https://t.co/up1xJS1nyd https://t.co/mtlQj86HWK
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
RT @TheLancet: Just added to The Lancet's #COVID19 Resource Centre—Safety and immunogenicity of two COVID-19 vaccine trials: ChAdOx1 https:…
RT @CR7DR: Yesss ! Yesss ! @LINCPAL @teoec1977 @GEORGESANCHEZ7 @dona_pily
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial https://t.co/16sXBnyEDF
Vamos!
RT @TheLancet: Just added to The Lancet's #COVID19 Resource Centre—Safety and immunogenicity of two COVID-19 vaccine trials: ChAdOx1 https:…
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
CanSino vaccine: Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial https://t.co/LoKQopFmsH
RT @iaiestaran: Vacuna china en fase 2 resulta segura y produce respuesta inmune en la epidemia de coronavirus #COVID19, según estudio publ…
RT @TheLancet: Just added to The Lancet's #COVID19 Resource Centre—Safety and immunogenicity of two COVID-19 vaccine trials: ChAdOx1 https:…
RT @FabBallarini: BUENAS NOTICIAS Se acaban de publicar 2 papers contando los avances sobre 2 vacunas. En ambos casos se muestra respuest…
@galenker @raspopoj The CanSinoBio paper takes a look at age. Older people to have a significantly lower immune response, but higher tolerability, so they might theoretically be able to take an extra dose to get a better immune response. https://t.co/RfOF4
RT @iaiestaran: Vacuna china en fase 2 resulta segura y produce respuesta inmune en la epidemia de coronavirus #COVID19, según estudio publ…
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
@PinzonAparicioE @nitoadames No hermano, NO ESTÁ LISTA! lo que CansinoBiologics ha mostrado son resultados de respuesta inmunológica por dicha vacuna “experimental”, pero no lo suficiente para fase 4; para llegue comercialmente y de forma mas segura y efic
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
RT @pmarsupia: 🔴 Más buenas noticias! The Lancet también ha publicado los resultados de la Fase II de la farmacéutica china CanSino (sí,…
RT @LLopezGonzalez: 4/4 Another experimental #COVID19 vaccine in China also released promising early results when researchers tested to see…
Studies on 2 Covid 19 vaccines published...Still a long way to go!
RT @TheLancet: Just added to The Lancet's #COVID19 Resource Centre—Safety and immunogenicity of two COVID-19 vaccine trials: ChAdOx1 https:…
RT @MAlhomrany: Lancet have published the data of phase 1,2 of two vaccines against #Covid_19.Both vaccines showed safety and produced reas…
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
RT @TheLancet: Just added to The Lancet's #COVID19 Resource Centre—Safety and immunogenicity of two COVID-19 vaccine trials: ChAdOx1 https:…
RT @AB_Algaissi: أخبار جميلة اليوم عن اللقاحات: نشر نتائج المرحلة السريرية ١ للقاح جامعة أكسفورد والنتائج مشجعة جداً. https://t.co/qzBJVYI…
RT @PleuralPOCUS: NUEVO: prueba china de fase 2 #COVID19 la vacuna es segura e induce una respuesta inmune https://t.co/HPXLQJgO2A https://…
RT @MAlhomrany: Lancet have published the data of phase 1,2 of two vaccines against #Covid_19.Both vaccines showed safety and produced reas…
RT @pmarsupia: 🔴 Más buenas noticias! The Lancet también ha publicado los resultados de la Fase II de la farmacéutica china CanSino (sí,…
RT @FabBallarini: BUENAS NOTICIAS Se acaban de publicar 2 papers contando los avances sobre 2 vacunas. En ambos casos se muestra respuest…
RT @TheLancet: Just added to The Lancet's #COVID19 Resource Centre—Safety and immunogenicity of two COVID-19 vaccine trials: ChAdOx1 https:…
RT @TheLancet: Just added to The Lancet's #COVID19 Resource Centre—Safety and immunogenicity of two COVID-19 vaccine trials: ChAdOx1 https:…
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
@EricTopol The CanSino program did break out CD4+ & CD8+ responses in phase 1: https://t.co/eb5hFNJxdg "IFNγ was detected from CD4+ and CD8+ T cells after the vaccination at day 14 and 28, in all dose groups..." and T-cell response in general in phas
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial https://t.co/evpLjP2tRN
RT @EricTopol: And another adenovirus vector vaccine Phase 2 trial (CanSIno) in China, published @TheLancet today, also found neutralizing…
CoVid-19 and very exciting news in the same sentence. Finally. The much anticipated results from the Oxford vaccine trial are extremely promising. This large trial of 1077 patients showed very good immune responses with robust antibody production by 28 da
Lancet have published the data of phase 1,2 of two vaccines against #Covid_19.Both vaccines showed safety and produced reasonable immunogenicity.Waiting for phase 3 before conclusion can be made. Preliminary results are promising https://t.co/caAY8evrse
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
RT @iaiestaran: Vacuna china en fase 2 resulta segura y produce respuesta inmune en la epidemia de coronavirus #COVID19, según estudio publ…
RT @iaiestaran: Vacuna china en fase 2 resulta segura y produce respuesta inmune en la epidemia de coronavirus #COVID19, según estudio publ…
RT @TheLancet: Just added to The Lancet's #COVID19 Resource Centre—Safety and immunogenicity of two COVID-19 vaccine trials: ChAdOx1 https:…
Salen los primeros estudios sobre dos de las vacunas que van adelantando sus pruebas. Una es la de Oxford, la otra es la CanSino de China. The Lancet los publica
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
RT @FaridaAlHabib1: #الكويت اللقاح الصيني في مرحلته الثانية ناجعا في اكثر من 95% وبجرعة واحدة فقط وآمن أحدث ضجة مفرحة حول العالم بعد ان ن…
RT @TheLancet: Just added to The Lancet's #COVID19 Resource Centre—Safety and immunogenicity of two COVID-19 vaccine trials: ChAdOx1 https:…
RT @TheLancet: Just added to The Lancet's #COVID19 Resource Centre—Safety and immunogenicity of two COVID-19 vaccine trials: ChAdOx1 https:…
RT @pokrath: Ref 1. mRNA vaccine https://t.co/hjEPxcG3sz 2. Oxford vaccine https://t.co/oDJwiMGYwl 3. Cansino vaccine (จีน) https://t.co/Tb…
RT @virolvlog: أخبار جيدة: أظهر دراستان نشرتا اليوم أن لقاح جامعة أكسفورد ولقاح شركة كانسينو الصينية (كلاهما يعتمد على تقنية ناقل أدينو) أث…
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
RT @mayogastro: Excelente. Esta vacuna parece efectiva con pocos efectos 2rios. Immunogenicity and safety of a recombinant adenovirus type-…
RT @anasdotscot: Progress. 👇
RT @FabBallarini: BUENAS NOTICIAS Se acaban de publicar 2 papers contando los avances sobre 2 vacunas. En ambos casos se muestra respuest…
RT @DrMHFriedlander: This is very exciting progress in the #COVID19 vaccine development.
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
RT @JackieUdeC: Y siguen los avances en la búsqueda de una vacuna segura y efectiva contra #COVID19. Estudios preliminares de la vacuna chi…
RT @iaiestaran: Vacuna china en fase 2 resulta segura y produce respuesta inmune en la epidemia de coronavirus #COVID19, según estudio publ…
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
RT @TheTrueTankMan: This is big.
RT @iaiestaran: Vacuna china en fase 2 resulta segura y produce respuesta inmune en la epidemia de coronavirus #COVID19, según estudio publ…
RT @JoeBriggsEsq: Here we go... off into the wild blue yonder... #TheRona https://t.co/h3EImGA5sg
Progress. 👇
RT @KnowC19_Burnet: 💉3rd vaccine result in the last 2 weeks💉 🙌🏽 Ad5-vectored COVID-19 vaccine. Single-dose immunisation in adults >18 yrs.…
Here we go... off into the wild blue yonder... #TheRona
RT @FabBallarini: BUENAS NOTICIAS Se acaban de publicar 2 papers contando los avances sobre 2 vacunas. En ambos casos se muestra respuest…
RT @TheLancet: Just added to The Lancet's #COVID19 Resource Centre—Safety and immunogenicity of two COVID-19 vaccine trials: ChAdOx1 https:…
RT @DrMHFriedlander: This is very exciting progress in the #COVID19 vaccine development.
RT @FabBallarini: BUENAS NOTICIAS Se acaban de publicar 2 papers contando los avances sobre 2 vacunas. En ambos casos se muestra respuest…
RT @ocram: aquí ambas publicaciones https://t.co/4mDkqjqWkD
RT @FabBallarini: BUENAS NOTICIAS Se acaban de publicar 2 papers contando los avances sobre 2 vacunas. En ambos casos se muestra respuest…
Chinese COVID19 vaccine is safe and induces an immune response. Phase 3 trial next.
RT @TheLancet: Just added to The Lancet's #COVID19 Resource Centre—Safety and immunogenicity of two COVID-19 vaccine trials: ChAdOx1 https:…
RT @JackieUdeC: Y siguen los avances en la búsqueda de una vacuna segura y efectiva contra #COVID19. Estudios preliminares de la vacuna chi…
Y siguen los avances en la búsqueda de una vacuna segura y efectiva contra #COVID19. Estudios preliminares de la vacuna china desarrollada por CanSino Biologics, Ad5-nCOV, demostró tener una respuesta inmune segura. Vía @TheLancet https://t.co/FK6nnjcdZh
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
This is very exciting progress in the #COVID19 vaccine development.
RT @iaiestaran: Vacuna china en fase 2 resulta segura y produce respuesta inmune en la epidemia de coronavirus #COVID19, según estudio publ…
RT @iaiestaran: Vacuna china en fase 2 resulta segura y produce respuesta inmune en la epidemia de coronavirus #COVID19, según estudio publ…
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…